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Abstract
Objectives. To determine the most sensitive and specific method of anti-Chlamydia
antibody measurement for the serodiagnosis of Chlamydia trachomatis reactive arthritis.
Methods. Immunoblotting, enzyme-linked immunosorbent assays using six synthetic peptides
or recombinant antigens and a microimmunofluorescence test were used to determine the
presence of IgG, IgM and IgA in serum samples from 17 patients with C. trachomatis reactive
arthritis. Twenty patients with other inflammatory arthropathies without evidence of urogenital
C. trachomatis infection were used as controls.
Results. The best association of sensitivity (76%) and specificity (85%) was obtained when IgG
anduor IgA reactivity to two species-specific antigens was determined. These antigens were
synthetic peptides, derived from species-specific epitopes in the variable domain IV of the major
outer membrane protein (MOMP) (Labsystems, Finland) and recombinant polypeptide encoded
by open reading frame 3 of the plasmid (pgp3).
Conclusions. IgG anduor IgA anti-MOMP-derived peptides and anti-pgp3 could be useful for
the diagnosis of probable C. trachomatis reactive arthritis.
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Reactive arthritis due to Chlamydia trachomatis is not
always associated with obvious urogenital symptoms.
Moreover, evidence of C. trachomatis infection by posi-
tive urethraluendocervical culture of bacteria or positive
antigen or DNA detection can be missing at the time of
the arthritis, and the diagnosis of the triggering infection
relies on serology. However, both the sensitivity and
specificity of serological tests need to be improved w1x.
In two previous studies, we compared serum anti-
Chlamydia antibody responses, obtained for patients
with well defined urethraluendocervical infection, with
those obtained for healthy blood donors. The best
sensitivity (86%) with a specificity of 81% was obtained
for immunoblot results, when the number of individuals
with 010 IgG anduor 02 IgM responses to the dif-
ferent C. trachomatis antigens was considered w2x. Con-
cerning antibody responses to peptides or recombinant
antigens, the best sensitivity (79%) associated with the
best specificity (82%) was obtained when IgG responses
to both synthetic peptides, derived from species-specific
epitopes in the variable domain IV of the major outer
membrane protein (MOMP) (Labsystems, Finland)
and recombinant polypeptide encoded by open reading
frame 3 of the plasmid (pgp3) were considered w3x. MOMP
is a surface-exposed, integral membrane protein of
approximately 40 kDa, found in both the extracellular
infectious elementary bodies and the non-infectious
intracellular reticulate bodies. Pgp3 is a protein of appro-
ximately 27 kDa, predominantly found in chlamydial
outer membrane complex preparation w4x.
Therefore, we evaluated whether these new assays can
also increase sensitivity and specificity of the sero-
logical diagnosis of C. trachomatis reactive arthritis.
The specificity was evaluated from samples of patients
with inflammatory arthropathies without evidence of
C. trachomatis infection, half of the cases being other
bacterial arthropathies. Such controls are necessary in
view of unspecific reactions possibly due to inflamma-
tion anduor presence of cross-reacting antibodies, due
to other bacterial infections.
Patients and methods
Patients
Diagnosis was taken from the chart at the time of
collection of the sera. They come from patients divided
into the two following groups:
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(i) Chlamydia trachomatis sexually-acquired reactive
arthritis (C. trachomatis-SARA) (n=17): asym-
metrical monouoligoarthritis with urethritis and
evidence of C. trachomatis infection wthree had a
positive urethraluendocervical C. trachomatis anti-
gen detection by direct immunofluorescence, 11
had a positive urethraluendocervical C. trachomatis
culture, three had a positive urethral C. trachomatis
DNA amplification with the Amplicor test of Roche
Diagnostic Systems Inc. (Branchburg, NJ)x; median
age, 26 yr (range 18–38), 29% of female patients,
62% of HLA-B27 positive patients.
(ii) Inflammatory arthropathies unrelated to C. tracho-
matis (n=20): gout (n=6), septic arthritis (n=5),
Lyme arthritis (diagnosis confirmed by western
blot) (n=3), rheumatoid factor positive rheumatoid
arthritis (n=3), post-dysenteric arthritis (n=2) and
oligoarthritis with positive Salmonella enteritidis
serology (n=1); median age, 39 yr (range 17–73),
25% of female patients.
Immunoblot analyses of sera
They were performed as previously described w5x.
Recombinant protein preparations and measurement
of antibodies to hsp70, OMP2, hsp60 and pgp3 by
enzyme-linked immunosorbent assays (ELISA),
measurement of antibodies to C. pneumoniae, MOMP-
derived peptides and LPS by commercially available
ELISA and microimmunofluorescent (MIF) tests
Experimental conditions were previously described w2, 3x.
Calculations
Sensitivity, specificity and agreement were calculated as
described previously w6x.
Statistical analysis
Where appropriate, results were analysed by the
chi-square test.
Results
Diagnostic value of the different antibody
determinations
A significantly higher number of C. trachomatis reactive
arthritis patients were found to have IgG antibodies to
MOMP-derived peptides, pgp3 and OMP2, and IgA
antibodies to MOMP-derived peptides, when compared
with the controls. The highest difference between both
groups was observed when IgG response to bothMOMP-
derived peptides and pgp3 was examined (P=0.0006)
(Table 1).
When positive responses to individual antigens were
considered, the highest sensitivity was obtained for IgG
anduor IgA anti-OMP2 (100%) but with a low specificity
(45%) and the highest specificity for IgG anduor IgA
anti-pgp3 (90%) with a sensitivity of 59%. When positive
responses to a combination of two antigens were
considered, the best diagnostic value was obtained for
IgG anduor IgA responses to MOMP-derived peptides
and pgp3 (sensitivity, 76%; specificity, 85%; agreement,
81%) (Table 2).





of C. trachomatis (n=20) Chi-test P
C. pneumoniae (Labsystems) IgG 60a 42b ns
IgM 0a 0b ns
IgA 10a 26b ns
Chlamydia LPS (Medac) IgG 88 70 ns
IgM 6 5 ns
IgA 65 35 ns
C. trachomatis MOMP-derived
peptides (Labsystems) IgG 47 15 0.034
IgA 29 5 0.045
Recombinant C. trachomatis proteins prepared in our laboratory
hsp70 IgG 35 35 ns
IgA 0 0 ns
hsp60 IgG 65 45 ns
IgA 18 5 ns
pgp3 IgG 59 10 0.0016
IgA 6 5 ns
OMP2 IgG 100a 55c 0.015
IgA 20a 27c ns
Best combination of antigens
MOMP-derived peptides + pgp3 IgG 71 15 0.0006
IgA 29 10 ns
an=10; bn=19; cn=11.
ns, not significant.
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A sensitivity of 69% with a specificity of 75% was
obtained for immunoblot results, when the number of
individuals with 010 IgG anduor 02 IgM responses to
the different C. trachomatis antigens was considered
(data not shown).
The MIF test was used to determine the presence of
anti-C. trachomatis antibodies in seven samples from
patients with C. trachomatis reactive arthritis. For IgG
measurement, 14% were found to be positive whereas
71% of these samples had IgG antibodies to the MOMP-
derived peptides and pgp3 (P=0.031). For IgA, no
sample was found to be positive with MIF test whereas
29% had IgA antibodies to the MOMP-derived peptides
and pgp3 (not significant) (data not shown).
Discussion
This study was performed to improve the serodiagnosis
of C. trachomatis reactive arthritis. The MIF test, still
considered as the gold standard for chlamydial serology,
was used to determine the presence of anti-C. trachomatis
antibodies in some samples from patients with C.
trachomatis reactive arthritis. Very poor sensitivities
were obtained: 14% for IgG and 0% for IgA whereas,
when theMOMP-derived peptides and pgp3 were used as
antigens, the sensitivities were 71 and 29%, respectively.
These results are similar to those we obtained with
samples from patients with acute C. trachomatis uro-
genital infection w2x. Several studies have also reported
that MIF sensitivity and specificity were lower than
generally appreciated w7–9x and MIF IgA has been found
to be the least sensitive assay in a study comparing five
different serological tests w10x.
In a previous study, comparing acute C. trachomatis
infected patients with healthy blood donors, we
obtained the best results with immunoblots, when the
number of individuals with 010 IgG anduor 02 IgM
responses was considered (sensitivity, 86%; specifi-
city, 81%) w2x. In the present study, using as controls,
patients with inflammatory arthropathies unrelated to
C. trachomatis, immunoblot results were found to be
less sensitive (69%) and specific (75%). This lower
sensitivity should be related to the observation we
made earlier that significantly fewer Chlamydia antigens
were recognized on the blots, by sera from patients with
reactive arthritis than by those with uncomplicated
C. trachomatis genito-urinary infection w5x. The lower
specificity obtained in this study, with samples from
patients with inflammatory arthropathies, compared
with the one obtained with samples from healthy
blood donors w2x suggests that some antibodies might
be elicited by other micro-organisms, as 50% of these
control patients had another bacterial infection. This
hypothesis is also supported by low specificities obtained
for IgG binding to other antigens tested in ELISA:
LPS (30%), OMP2 (45%) and hsp60 (55%). As LPS
and OMP2 are genus-specific antigens, low specificities
obtained with them can be attributed to cross-reactivity
with C. pneumoniae as 42% of these patients had IgG
antibodies to it. If cross-reactivity to C. pneumoniae can
also be involved for hsp60 recognition w3x, cross-reactivity
to other bacterial hsp60 is also possible because, for half
of them, the arthropathy was dependent on Borrelia
burgdorferi, Brucella or Staphylococcus aureus.
The most appropriate tests for the serodiagnosis of
patients with C. trachomatis reactive arthritis were
found to be IgG anduor IgA reactivity to MOMP-
derived peptides + pgp3. Compared with a previous
study w1x, a lower sensitivity was obtained for MOMP-
derived peptide antibodies, due to a modification of the
cut-off calculation indicated by the manufacturer
(Labsystems).
In conclusion, since C. pneumoniae infections are
common and able to elicit cross-reacting antibodies,
such as anti-LPS, -OMP2 or -hsp60 and since other
bacterial infections, involved in inflammatory arthro-
pathies, are also able to elicit cross-reacting antibodies
such as anti-hsp60, only species-specific antigens, such
as MOMP-derived peptides or pgp3, should be used.
TABLE 2. Best sensitivities, specificities and agreement obtained for the different anti-Chlamydia antibody assays
Sensitivity (%) Specificity (%) Agreement (%)
IgG anduor IgA anti-LPS 94 20 54
IgG anduor IgA anti-MOMP-derived peptides 53 85 70
IgG anduor IgA anti-hsp60 71 50 59
IgG anduor IgA anti-pgp3 59 90 76
IgG anduor IgA anti-OMP2 100 45 71
IgG anduor IgA anti-LPS + MOMP-derived peptides 94 20 54
IgG anduor IgA anti-LPS + hsp60 94 20 54
IgG anduor IgA anti-LPS + pgp3 94 20 54
IgG anduor IgA anti-LPS + OMP2 100 18 57
IgG anduor IgA anti-MOMP-derived peptides + hsp60 82 50 65
IgG anduor IgA anti-MOMP-derived peptides + pgp3 76 85 81
IgG anduor IgA anti-MOMP-derived peptides + OMP2 100 45 71
IgG anduor IgA anti-hsp60 + pgp3 82 50 65
IgG anduor IgA anti-hsp60 + OMP2 100 36 67
IgG anduor IgA anti-pgp3 + OMP2 100 45 71
Positive patients were 10–17 patients with C. trachomatis reactive arthritis and negative patients were 11–20 patients with inflammatory
arthropathies independent of C. trachomatis.
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The improvement of sensitivity and specificity obtained
with recombinant pgp3 prepared under native condi-
tions (in order to retain an antigenic structure able to
detect antibodies directed to conformational epitopes)
is shown for the first time in the serodiagnosis of this
disease. Finally, if the MIF test is the most documented
serological method and is commonly accepted as the
reference assay, we did not find it as the best test.
ELISA using MOMP-derived peptides or pgp3 are rapid
methods, completely objective, giving reproducible results,
easier to perform than the MIF test and appeared to be
more helpful in the serodiagnosis of C. trachomatis
reactive arthritis. However, due to the difficulty of
having well characterized patients with this uncommon
disease, the number of samples tested was small and the
results obtained with these tests should be confirmed in
bigger studies.
Acknowledgements
The technical assistance of Yvette Froment, Ursula
Spenato and Monique Stucker is gratefully acknow-
ledged. This study was supported by grant nos
32-47299.96 and 3200-061500.00 from the Fonds
National Suisse de la Recherche Scientifique.
References
1. Bas S, Vischer TL. Chlamydia trachomatis antibody detec-
tion and diagnosis of reactive arthritis. Br J Rheumatol
1998;37:1054–9.
2. Bas S,Muzzin P,Ninet B, Bornand JE, Scieux C, Vischer TL.
Chlamydial serology: comparative diagnostic value
of immunoblotting, microimmunofluorescence test, and
immunoassays using different recombinant proteins as
antigens. J Clin Microbiol 2001;39:1368–77.
3. Bas S, Muzzin P, Vischer TL. Chlamydia trachomatis
serology: diagnostic value of outer membrane protein 2
compared with that of other antigens. J Clin Microbiol
2001;39:4082–5.
4. Comanducci M, Cevenini R, Moroni A et al. Expression
of a plasmid gene of Chlamydia trachomatis encoding a
novel 28 kDa antigen. J Gen Microbiol 1993;139:1083–92.
5. Bas S, Scieux C, Vischer TL. Male sex predominance in
Chlamydia trachomatis sexually acquired reactive arthri-
tis: are women more protected by anti-chlamydia anti-
bodies? Ann Rheum Dis 2001;60:605–11.
6. Bas S, Cunningham T, Kvien TK, Glennas A, Melby K,
Vischer TL. The value of isotype determination of serum
antibodies against Chlamydia for the diagnosis of Chla-
mydia reactive arthritis. Br J Rheumatol 1996;35:542–7.
7. Moss TR, Darougar S, Woodland RM, Nathan M,
Dines RJ, Cathrine V. Antibodies to Chlamydia species
in patients attending a genitourinary clinic and the impact
of antibodies to C. pneumoniae and C. psittaci on the
sensitivity and the specificity of C. trachomatis serology
tests. Sex Transm Dis 1993;20:61–5.
8. Biendo M, Eb F, Lefebvre JF, Orfila J. Limits of the
microimmunofluorescence test and advantages of immuno-
blotting in the diagnosis of chlamydiosis. Clin Diagn Lab
Immunol 1996;3:706–9.
9. Wagenvoort JH, Koumans D, van de Cruijs M. How
useful is the Chlamydia micro-immunofluorescence (MIF)
test for the gynaecologist? Eur J Obstet Gynecol Reprod
Biol 1999;84:13–5.
10. Clad A, Freidank HM, Kunze M et al. Detection of
seroconversion and persistence of Chlamydia trachomatis
antibodies in five different serological tests. Eur J Clin
Microbiol Infect Dis 2000;19:932–7.
1020 S. Bas et al.
